Back

Metabolomics differentiate cancer from non-cancer pleural effusions based on steroid lipids and acyl carnitines

da Costa, R.; Love, K.; Beckmann, M.; Morley, A.; Bhatnagar, R.; Maskel, N.; Mur, L. A.; Lewis, K.

2020-07-29 respiratory medicine
10.1101/2020.07.27.20162958 medRxiv
Show abstract

ObjectiveTo identify and detect metabolomic markers to differentiate cancer related from other pleural effusions. Material and methodsUn-targeted flow infusion electrospray mass spectrometry was used on a cohort of 100 samples from benign and malignant pleural effusions (12 primary lung cancers, 14 mesotheliomas, 24 other cancers, 25 congestive cardiac failure, 22 parapneumonic effusion, 3 empyema). Standard metabolomic statistical models for analysis were performed. ResultsFive novel markers were identified using univariate and multivariate receiving operator curve analyses using five discriminant features yielding a diagnostic accuracy of above 0.91 (95% CI: 0.839-0.976) with a sensitivity of 0.97 (95% CI 0.952-0.979) and specificity 0.87 (95% CI 0.852-0.894). ConclusionIndividual biomarkers with the highest accuracy (>0.84) were all raised in cancer and are involved in metabolism of sterol-lipids and acyl carnitines linked to {beta}-oxidation. Our markers performed better than those previously published. Further, these published markers failed to achieve their stated accuracies in our data.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.